EHVA T02 / ANRS VRI07 is a Phase II placebo-controlled randomised trial that is evaluating an experimental therapeutic HIV vaccine, MVA HIV-B, and an antibody-based immunotherapy drug, vedolizumab, for people living with HIV. The trial is taking place in France, Germany, Switzerland, and the UK and will evaluate the safety and tolerability of the experimental vaccine with the antibody, or the antibody alone. Further, this trial will see if either regimen can control HIV infection following interruption of antiretroviral therapy in individuals who started antiretroviral therapy during primary or chronic infection.

The trial is sponsored by Inserm-ANRS, an autonomous agency of the French National Institute of Health and Medical Research in the field of HIV and hepatitis research and managed by The Medical Research Council Clinical Trials Unit at University College London. The European AIDS Treatment Group serves as the community engagement partner. Other EHVA member institutions will provide immunological and statistical analyses, as well as data management, data analysis and pharmacovigilance.

Click here to read the full press release for EHVA-T02.

For more information, read the EHVA-T02 Q&A, available in four languages:



This project has received funding from the European Union's Horizon 2020 research
and innovation programme under grant agreement N° 681032